[Inventory] 15 most influential people in the global medical field in 2016
In 2016, just after the wonderful year of the medical industry, the cooperation and progress of the global bioscience and mobile medical fields have become more and more intense, from the world-renowned medical research program to the next generation of genetic testing and gene editing of cells. Sequencing and mechanisms, stem cell applications, and the promotion of medical trials and practices with big data and artificial intelligence, there are countless practitioners working hard to bring better medical solutions to all of humanity.
The author has compiled the political dynamics, medical achievements, and medical innovations of the past year, and has referenced the 2016 list of authoritative media such as Forbes and the Times, as well as the annual character events of authoritative academic journals such as Science and Nature. Among the people who have made outstanding contributions to the global medical community in the past year, 15 people from all walks of life who have made great influences have been selected to see how they lead the medical trend.
Political
Barack Obama
For the United States, the outgoing president has been pushing the affordable medical bill for the public health status with great enthusiasm; for the future of the world's medical care, Obama also contributed the 21st Century Healing Act for the medical future.
On December 13, Obama completed the signing of the bill in the final phase of his term. On the one hand, the FDA's approval and authorization for drugs and medical devices will be accelerated; on the other hand, basic medical research is highlighted, and will focus on precision medical programs, Cancer Moonshot, Alzheimer's disease research, etc. Invested about $6.3 billion in funding.
Joe Biden
On January 12, 2016, Obama’s last State of the Union address announced the “Cancer Moon Planâ€, led by US Vice President Biden.
Biden’s eldest son, Bo Biden, died of brain cancer in May 2015, only 46 years old. The pain of losing the child made Biden give up the 2016 presidential campaign and fully promote the anti-cancer cause during the remaining vice presidential term.
The “moon landing team†proposed the strategic goals for the next five years: First, “catalyze new scientific breakthroughsâ€, including several projects in 10 cancer fields proposed by the NCI (National Cancer Institute) in September this year; It is the “power to release dataâ€, which is the NCI genome data sharing project launched last year. The research data of many cancer patients are included in the database and classified and described. The third is to promote the development of clinical trials to bring new treatments to patients, for example. NCI's anti-cancer test database to enhance patient-to-clinical testing.
Donald Trump
The new president is very self-assertive in American medical care. The abolition of government health insurance subsidies and the use of tax cuts to make up for, promote insurance across states and liberalize the import of prescription drugs, and promote price transparency are all new styles of this “business-oriented leadership†approach to the United States.
The controversy caused by Trump's medical reform proposition has never been less. Some people worry that after Trump takes office, it will reduce the funding of medical research and affect the progress of life sciences in the United States and the world. However, the new presidential government is undoubtedly carefully planning new tricks, and the global medical research community in the next few years will also undergo certain changes under his influence.
The chemical formula of enzalutamide is 4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thione -1-imidazolidinyl]-2-fluoro-N-methylbenzamide, its clinical drug was jointly developed by Medivation and Astellas, and approved by the US Food and Drug Administration on August 31, 2012 FDA-approved for the treatment of advanced male castration-resistant prostate cancer that has spread or recurred under the trade name Xtandi[1], which is available as an oral preparation. Enzalutamide (MDV 3100) is an androgen receptor antagonist that blocks androgen binding to the androgen receptor and prevents nuclear translocation and coactivator recruitment of the ligand-receptor complex. MDV 3100 has also been shown to induce tumor cell apoptosis and has no agonist activity. MDV 3100 is a candidate for the treatment of castration-resistant prostate cancer.
Cas 143782-23-4,Enzalutamide Intermediates,6-Bromo-2-Chloro-8-Cyclopentyl
Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd , https://www.dingminpharma.com